Gene editing moves from labs to prescriptions. Longevity and cure focus.
Next-generation gene editing that programs biology with software-like precision.
First CRISPR therapies approved, proving the commercial pathway.
Newer editing tools offer precision that earlier versions lacked.
Aging populations and longevity investors fund aggressive R&D.
First gene therapies approved; pipeline expansion underway.
Broader indications and delivery improvements reach patients.
Prevention-focused genetic interventions become standard.
One-time cures replacing lifelong symptom management.
Engineered immune cells targeting specific cancers.
Crops engineered for climate resilience and nutrition.
Monitor clinical trial phases and regulatory milestones.
Companies with multiple applications reduce single-program risk.
Delivery and production capabilities determine scale.
New gene therapies reaching market validation.
Efficacy and safety results from ongoing studies.
Big pharma licensing platform technologies.
Newer tools like base editing and prime editing offer more precise changes with fewer unintended effects.
Current therapies are expensive, but pricing models are evolving as competition increases.
Safety in broader populations, manufacturing challenges, and reimbursement uncertainty.